According to a Danish study published on Wednesday, administering a third dosage of either Pfizer-or BioNTech's Moderna's Covid-19 vaccine provides a substantial boost in immunity against the Omicron variant in aged people.
The study, which has not yet been peer-reviewed, looked into the efficacy of Covid-19 vaccines based on mRNA technology against the Delta variant and the new, more infectious Omicron variant.
"Our study contributes to emerging evidence that BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) primary vaccine protection against Omicron decreases quickly over time, with booster vaccination offering a significant increase in protection," the authors wrote in the study.
Researchers at Denmark's main infectious disease agency, Statens Serum Institut, performed the investigation (SSI). It looked at data from three million Danes who were polled between November 20 and December 12.
In comparison to unvaccinated people, the efficiency of Pfizer-BioNTech and 36.7 percent for Moderna against Omicron was evaluated at 55.2 per cent for Pfizer-BioNTech and 36.7 percent for Moderna among those who recently received their second vaccine dosage.
The protection, however, quickly wore off over the course of five months, according to the researchers.
"We see that the protection is lower and decreases faster against Omicron than against the Delta variant after a primary vaccination course," study author Palle Valentiner-Branth said.
For those aged 60 years and over who had been immunised 14 to 44 days before, a third dosage of Pfizer-vaccine BioNTech's maintained immunity to 54.6 per cent, relative to those who had only two doses.
The results of the study back up those of an earlier British study, which found a quick reduction in Omicron resistance over time and an increase after a booster with Pfizer-vaccine. BioNTech's
"In light of the exponential rise in Omicron cases, these findings highlight the need for massive rollout of vaccinations and booster vaccinations," the researchers said.
(Source:www.reuters.com)
The study, which has not yet been peer-reviewed, looked into the efficacy of Covid-19 vaccines based on mRNA technology against the Delta variant and the new, more infectious Omicron variant.
"Our study contributes to emerging evidence that BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) primary vaccine protection against Omicron decreases quickly over time, with booster vaccination offering a significant increase in protection," the authors wrote in the study.
Researchers at Denmark's main infectious disease agency, Statens Serum Institut, performed the investigation (SSI). It looked at data from three million Danes who were polled between November 20 and December 12.
In comparison to unvaccinated people, the efficiency of Pfizer-BioNTech and 36.7 percent for Moderna against Omicron was evaluated at 55.2 per cent for Pfizer-BioNTech and 36.7 percent for Moderna among those who recently received their second vaccine dosage.
The protection, however, quickly wore off over the course of five months, according to the researchers.
"We see that the protection is lower and decreases faster against Omicron than against the Delta variant after a primary vaccination course," study author Palle Valentiner-Branth said.
For those aged 60 years and over who had been immunised 14 to 44 days before, a third dosage of Pfizer-vaccine BioNTech's maintained immunity to 54.6 per cent, relative to those who had only two doses.
The results of the study back up those of an earlier British study, which found a quick reduction in Omicron resistance over time and an increase after a booster with Pfizer-vaccine. BioNTech's
"In light of the exponential rise in Omicron cases, these findings highlight the need for massive rollout of vaccinations and booster vaccinations," the researchers said.
(Source:www.reuters.com)
